1. Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. Issue 4 (31st July 2019) Authors: Nevala-Plagemann, Christopher; Moser, Justin; Gilcrease, Glynn Weldon; Garrido-Laguna, Ignacio Journal: ESMO open Issue: Volume 4:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗